

Resource Summary Report

Generated by [NIF](#) on Sep 12, 2026

U266B1

RRID:CVCL_0566

Type: Cell Line

Proper Citation

RRID:CVCL_0566

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0566

Proper Citation: RRID:CVCL_0566

Description: Cell line U266B1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Plasma cell myeloma

Defining Citation: [PMID:1373872](#), [PMID:1643757](#), [PMID:1720489](#), [PMID:2140233](#), [PMID:2537114](#), [PMID:2985879](#), [PMID:3159941](#), [PMID:3874327](#), [PMID:4097745](#), [PMID:4104421](#), [PMID:6350451](#), [PMID:8943038](#), [PMID:9685479](#), [PMID:10087940](#), [PMID:10557056](#), [PMID:10583232](#), [PMID:10936422](#), [PMID:11154231](#), [PMID:11157491](#), [PMID:11429052](#), [PMID:14555701](#), [PMID:15215163](#), [PMID:16956823](#), [PMID:17171682](#), [PMID:17229644](#), [PMID:17692805](#), [PMID:18647998](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21173094](#), [PMID:22460905](#), [PMID:22806891](#), [PMID:23074853](#), [PMID:23992230](#), [PMID:25485619](#), [PMID:25688540](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30545397](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:32123307](#), [PMID:35839778](#)

Comments: Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck, Catherine., Characteristics: Produces IgE lambda., Population: Caucasian., Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981)., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Hybridoma fusion partner cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: U266B1

Synonyms: U266-B1, U266 B1, U-266, U 266, U266, U266S, U266BL, U266 BI, 266 BI

Cross References: BTO:BTO_0001594, CLO:CLO_0009457, CLO:CLO_0009458, EFO:EFO_0001254, MCCL:MCC:0000471, CLDB:cl4584, CLDB:cl4609, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ArrayExpress:E-TABM-937, ATCC:TIB-196, BCRC:60437, BCRJ:0240, BioSample:SAMN01821605, BioSample:SAMN01821669, BioSample:SAMN03472935, BioSample:SAMN10987866, cancercellines:CVCL_0566, CCRID:1101HUM-PUMC000684, CCRID:4201HUM-CCTCC00325, CCTCC:GDC0301, CCTCC:GDC0325, Cell_Model_Passport:SIDM00417, CGH-DB:37-1, CGH-DB:9155-4, ChEMBL-Cells:ChEMBL3308535, ChEMBL-Targets:ChEMBL2366315, CLS:300259, Cosmic:720795, Cosmic:742953, Cosmic:753615, Cosmic:759903, Cosmic:759912, Cosmic:760401, Cosmic:760647, Cosmic:886087, Cosmic:888019, Cosmic:991555, Cosmic:1424220, Cosmic:1483078, Cosmic:1762463, Cosmic:1889513, Cosmic:2081409, Cosmic:2159571, Cosmic:2367281, Cosmic:2391806, Cosmic:2809754, Cosmic-CLP:753615, DepMap:ACH-000626, DSMZ:ACC-9, DSMZCellDive:ACC-9, ECACC:85051003, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:753615, GEO:GSM143345, GEO:GSM545498, GEO:GSM545499, GEO:GSM562821, GEO:GSM827442, GEO:GSM887721, GEO:GSM888815, GEO:GSM1374970, GEO:GSM1670556, IARC_TP53:361, IARC_TP53:30185, IBRC:C10148, IGRhCellID:U266B1, IZSLER:BS TCL 233, KCB:KCB 2013024YJ, LiGeA:CCLE_465, LINCS_LDP:LCL-2050, Lonza:106, Lonza:807, NCBI_Iran:C151, PharmacDB:U266B1_1630_2019, PRIDE:PXD030304, Progenetix:CVCL_0566, PubChem_Cell_line:CVCL_0566, Wikidata:Q54973634

ID: CVCL_0566

Record Creation Time: 20220427T221640+0000

Record Last Update: 20260905T182616+0000

Ratings and Alerts

No rating or validation information has been found for U266B1.

Warning: Discontinued: BCRJ; 0240

Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck, Catherine., Characteristics: Produces IgE lambda., Population: Caucasian., Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981)., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Hybridoma fusion partner cell line.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 676 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. *Cell reports*, 45(6), 117464.

Tang A, et al. (2026) Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. *Cell reports. Medicine*, 7(3), 102628.

Lesire L, et al. (2026) Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin-degrading enzyme, a new molecular vulnerability in multiple myeloma. *British journal of pharmacology*, 183(12), 3355.

Lin P, et al. (2026) CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models. *Blood cancer discovery*, 7(2), 234.

Yang Z, et al. (2026) Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancer. *Cell reports. Medicine*, 7(2), 102613.

Tang K, et al. (2026) Targeting PRKCN, an Essential Driver Orchestrating mTOR-IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(21), e18975.

Cholujova D, et al. (2026) Anti-myeloma activity of the CXCR4 antagonist WZ811. *Journal of molecular medicine (Berlin, Germany)*, 104(1), 45.

Li S, et al. (2025) Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma. *Advanced healthcare materials*, e02156.

Tran S, et al. (2025) Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma. *Blood neoplasia*, 2(1), 100050.

Rodríguez-Lobato LG, et al. (2025) Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited. *Cancer immunology research*, 13(9), 1374.

Manara P, et al. (2025) Blocking NRF2 Translation by Inhibition of Cap-Dependent Initiation Sensitizes Lymphoma Cells to Ferroptosis and CAR T-cell Immunotherapy. *Cancer research*.

Weber J, et al. (2025) ROR2-specific CAR T cells are effective against hematologic and solid tumors and well tolerated in mice. *Cell reports. Medicine*, 6(10), 102400.

Lin AY, et al. (2025) Targeting scavenger receptor class B type 1 with a bioinspired ligand induces apoptosis or ferroptosis in AML. *Blood neoplasia*, 2(4), 100122.

Murphy CS, et al. (2025) Inhibition of acyl-CoA synthetase long-chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction. *Molecular oncology*, 19(6), 1687.

Cardona-Benavides IJ, et al. (2025) Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation. *Molecular oncology*.

Xu MX, et al. (2025) A novel synthesised STAT3 inhibitor exerts potent anti-tumour activity by inducing lysosome-dependent cell death. *British journal of pharmacology*, 182(17), 4041.

Venetz-Arenas N, et al. (2025) Development of DARPin T cell engagers for specific targeting of tumor-associated HLA/peptide complexes. *iScience*, 28(12), 113926.

Huang X, et al. (2025) CDK4/6 Inhibition Reverses MEIS2 Suppression of CRL4 CRBN to Enhance Immunomodulatory Drug Therapy in Multiple Myeloma. *bioRxiv : the preprint server for biology*.

Di Meo F, et al. (2025) Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma. *Cancer cell*, 43(12), 2298.

Yehia R, et al. (2025) A somatic multiple myeloma mutation unravels a mechanism of oligomerization-mediated product inhibition in GGPPS. *The FEBS journal*.